Proteostasis Therapeutics (Proteostasis Therapeutics) Median PS Value : $0.00 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Proteostasis Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $0. Proteostasis Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-26), Proteostasis Therapeutics's share price is $1.11. Proteostasis Therapeutics's Median PS Value is $0.00. Therefore, Proteostasis Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Proteostasis Therapeutics's Median PS Value or its related term are showing as below:

PTI's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.64
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Proteostasis Therapeutics Median PS Value Historical Data

The historical data trend for Proteostasis Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteostasis Therapeutics Median PS Value Chart

Proteostasis Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Median PS Value

Get a 7-Day Free Trial

Proteostasis Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Median PS Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Proteostasis Therapeutics's Median PS Value

For the Biotechnology subindustry, Proteostasis Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteostasis Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Proteostasis Therapeutics's Price-to-Median-PS-Value falls into.

Proteostasis Therapeutics Median PS Value Calculation

Proteostasis Therapeutics's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0	*
	=	0.00

10-Year Median PS Ratio is .
Proteostasis Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

Proteostasis Therapeutics (NAS:PTI) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Proteostasis Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	1.11	/	0.00
	=

Proteostasis Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135

Website

http://www.proteostasis.com

Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri	officer: Interim Head of Finance	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra	director, officer: President and CEO	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson	officer: Chief Operating Officer	C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz	officer: Chief Scientific Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson	officer: See Remarks	C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202